메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 28, Issue 2, 2010, Pages
Platinum-based second-line treatment in non-small-cell lung cancer: An old new kid on the block?
Author keywords

[No Author keywords available]
Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; IRINOTECAN; NAVELBINE; PEMETREXED; PLATINUM; PROTEIN MSH2; TAXANE DERIVATIVE; PLATINUM DERIVATIVE;
EID: 74949122648     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.1157     Document Type: Letter
Times cited : (4)
References (7)
  • 1
    • 65349091355 scopus 로고    scopus 로고
    • Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
    • Smit EF, Burgers SA, Biesma B, et al: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27:2038-2045, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 2038-2045
    • Smit, E.F.1    Burgers, S.A.2    Biesma, B.3
  • 2
    • 84871466073 scopus 로고    scopus 로고
    • Outcomes of advanced stage non-small cell lung cancer (NSCLC) patients reexposed to platinum-based chemotherapy upon progression
    • suppl; abstr 17136, 677s
    • Souza PH, Rodrigues AN, Dienstmann R, et al: Outcomes of advanced stage non-small cell lung cancer (NSCLC) patients reexposed to platinum-based chemotherapy upon progression. J Clin Oncol 24:677s, 2006 (suppl; abstr 17136)
    • (2006) J Clin Oncol , vol.24
    • Souza, P.H.1    Rodrigues, A.N.2    Dienstmann, R.3
  • 3
    • 27144466737 scopus 로고    scopus 로고
    • Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomised phase II study
    • Georgoulias V, Agelidou A, Syrigos K, et al: Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomised phase II study. Br J Cancer 93:763-769, 2005
    • (2005) Br J Cancer , vol.93 , pp. 763-769
    • Georgoulias, V.1    Agelidou, A.2    Syrigos, K.3
  • 4
    • 63849290363 scopus 로고    scopus 로고
    • Potential treatment options after first-line chemotherapy for advanced NSCLC: Maintenance treatment or early second-line?
    • Gridelli C, Maione P, Rossi A, et al: Potential treatment options after first-line chemotherapy for advanced NSCLC: Maintenance treatment or early second-line? Oncologist 14:137-147, 2009
    • (2009) Oncologist , vol.14 , pp. 137-147
    • Gridelli, C.1    Maione, P.2    Rossi, A.3
  • 5
    • 0037214171 scopus 로고    scopus 로고
    • A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
    • Massarelli E, Andre F, Liu D, et al: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39:55-61, 2003
    • (2003) Lung Cancer , vol.39 , pp. 55-61
    • Massarelli, E.1    Andre, F.2    Liu, D.3
  • 6
    • 70349722075 scopus 로고    scopus 로고
    • MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer
    • suppl; abstr CRA7502, 382s
    • Fouret P, Planchard D, Mendiboure J, et al: MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer. J Clin Oncol 27:382s, 2009 (suppl; abstr CRA7502)
    • (2009) J Clin Oncol , vol.27
    • Fouret, P.1    Planchard, D.2    Mendiboure, J.3
  • 7
    • 61749088474 scopus 로고    scopus 로고
    • Economics of treatments for non-small cell lung cancer
    • Chouaid C, Atsou K, HejblumG, et al: Economics of treatments for non-small cell lung cancer. Pharmacoeconomics 27:113-125, 2009
    • (2009) Pharmacoeconomics , vol.27 , pp. 113-125
    • Chouaid, C.1    Atsou, K.2    HejblumG3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.